JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY(英文缩写 J CANCER RES CLIN),ISSN 0171-5216,eISSN 1432-1335 是一本学术期刊。本页汇总该期刊的最新影响因子、分区信息以及最新收录于 PubMed 的文献,帮助您快速了解期刊全貌。
发文量统计区间：2025-09-28 至 2026-09-28，按本站收录文献的发表日期统计。
期刊介绍
历年影响因子趋势
| JCR 数据年份 | 影响因子 | JCR 分区 |
|---|---|---|
| 2021 | 4.322 | Q2 |
| 2022 | 3.600 | Q2 |
| 2023 | 2.700 | Q3 |
| 2024 | 2.800 | Q2 |
| 2025 | 3.300 | Q2 |
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY 最新收录文献
-
1. Comment on "Theranostic lipid nanocarriers for precision diagnosis and targeted therapy in pancreatic ductal adenocarcinoma".
PMID:日期:2026-09-25This letter comments on a recent review of theranostic lipid nanocarriers for pancreatic ductal adenocarcinoma, identifying three areas of concern in the evidence base. First, the 211-item reference list contains multiple duplicated citations listed under separate numbers with identical content (for example, refs. 6/8, 9/21, 55/89, 106/117, 132/143), a recurring pattern suggesting that the bibliography was not fully verified before submission. Second, Table 6 cites reference markers "[639]" and "[640]" for the NanoSMART and NBTXR3 trials, numbers that exceed the 211-entry reference list and appear to be residual artifacts from a source document with a different numbering scheme. Third, the review reports that NC-6004 (a micellar cisplatin formulation) has completed a phase III trial in combination with gemcitabine but omits the trial's outcome, despite the review's broader argument for the translational viability of lipid- and micelle-based nanocarriers and its extended discussion of nab-paclitaxel as a successful precedent. Reporting this outcome, favorable or not, alongside existing precedents, would allow readers to weigh the review's central claim against the complete record of late-stage clinical testing. While the review offers a valuable catalogue of nanocarrier platforms and regulatory precedents, these issues warrant correction before the citation base is treated as fully reliable.
-
2. Sleep quality and disturbances in adolescents and young adults with cancer compared to a healthy comparison group: results of the AYA-LE study.
PMID:日期:2026-09-22Adolescents and young adults (AYAs) with cancer often exhibit riskier health behaviors, including poorer sleep patterns, compared to older individuals. Research on the relationship between cancer and sleep quality in AYA patients has yielded inconsistent results. This study investigates sleep quality in AYA patients compared to a healthy comparison group and examines associated sociodemographic, clinical, and psychosocial variables as well as physical activity. The prospective observational study included 407 AYA patients aged 18-39 years at diagnosis and 372 healthy participants aged 18-45 years, with data collected from May-September 2019. Sleep quality was assessed using the Pittsburgh Sleep Quality Index (PSQI). Validated questionnaires measured self-efficacy, social support, anxiety, depression, quality of life, lack of energy, and physical activity. Multiple regression analyses were employed to explore the variables associated with sleep quality. The mean age of the AYA patients was 34.8 years (75.2% women) and 32.3 years of the healthy participants (61.8% women). AYA patients demonstrated significantly poorer subjective sleep quality (d=0.31), lower sleep efficiency (d=0.15), more frequent sleep disturbances (d=0.23), greater use of sleep medication (d=0.25), and higher daytime dysfunction (d=0.29). Anxiety, depression (HADS), quality of life (EORTC), and unmet needs for support through lack of energy (SCNS) were significantly associated with PSQI (adjusted R=0.35). These findings underscore the relevance of sleep disturbances in AYA patients and support greater attention to sleep disturbances in survivorship care. Routine assessment of sleep quality may help identify AYA patients who could benefit from further evaluation and appropriate support.
-
4. Upper- versus lower-extremity synovial sarcoma: distinct surgical pathways and postoperative morbidity in a 24-year cohort.
PMID:日期:2026-09-18Synovial sarcoma is a rare, late-relapsing soft-tissue sarcoma of the extremities. Whether anatomical location shapes the surgical treatment pathway, rather than prognosis alone, is unclear. We compared upper-extremity (UE) and lower-extremity (LE) tumors with respect to margin status, re-excision, reconstruction, morbidity and long-term oncological events. Retrospective single-center cohort of 59 consecutive patients with histologically confirmed extremity synovial sarcoma treated between 2000 and 2023. Co-primary endpoints were a microscopically positive margin (R1) at the index resection and any postoperative complication within 8 weeks (Clavien-Dindo). Metastasis-free survival (MFS) and overall survival were exploratory. Fisher exact, Mann-Whitney U, Kaplan-Meier and log-rank methods were used; odds ratios (OR) are UE relative to LE. Twenty-three tumors were UE and 36 LE. R1 at the index resection was more frequent in UE tumors (14/23 [61%] vs. 5/36 [14%]; OR 9.64, 95% CI 2.73-34.1; P < 0.001), as was neoadjuvant therapy (39% vs. 8%; P = 0.007). Definitive R0 was achieved in all patients. Any postoperative complication (13% vs. 53%; OR 0.13, 95% CI 0.03-0.53; P = 0.002) and major complications (9% vs. 39%; P = 0.015) were more frequent after LE surgery. Seven of nine distant metastases occurred in LE tumors, several beyond six years; ten-year MFS was 90% versus 56% (log-rank P = 0.095). Upper- and lower-extremity synovial sarcomas followed distinct surgical pathways and carried distinct morbidity profiles, whereas definitive R0 resection was attained in both. The time-to-event findings are exploratory and require multicenter validation.
-
8. Time to subsequent therapy (TTST) as an endpoint in clinical studies: development of standardized documentation of subsequent therapy through systematic literature review, expert interviews, and Delphi survey.
PMID:日期:2026-09-02The endpoint Time to Subsequent Therapy (TTST) is an intermediate endpoint used in research and regulatory assessments. TTST denotes initiation of subsequent therapy and is a clearly definable, clinically relevant event for healthcare professionals. However, it has not been systematically established to which extent TTST is subjectively meaningful to patients. The objective of this study was to define TTST as a patient-relevant intermediate endpoint. The study examined five oncological indications (breast cancer, prostate cancer, melanoma, multiple myeloma, and non-small cell lung cancer) using a systematic literature review, analysis of case report forms used in international randomized controlled trials, review of German Federal Joint Committee (G-BA) documents, semi-structured interviews and a two-stage Delphi survey with healthcare professionals, patients, and relatives. A total of 35 individuals participated in qualitative interviews. Most of them rated TTST as particularly significant. The Delphi Survey included 264 interviewees in round one, and 117 in round two. Patient-relevance of TTST was confirmed by 81% of respondents (95% confidence interval 76%, 85%). Nine treatment scenarios that justify TTST were identified. To capture patient-relevance, prospective collection of reasons for and consequences of therapy change are required. A checklist with standardized response formats plus free-text fields was developed: a comprehensive master checklist for flexible, complete documentation and a short version focused on therapy change-specific items. TTST is an intermediate endpoint whose systematic documentation of characteristics demonstrating patient-relevance can be standardized in research and clinical practice using the developed checklists.
-
9. Optimized surgical treatment and study management for oncology patients in East Saxony (MISSION4Sax): study protocol of a multicentre pilot study.
PMID:日期:2026-09-02MISSION4Sax aims to develop and pilot new concepts for cross-sectoral oncological care, data integration and networking between maximum care centres and rural practitioners in medical underserved, enabling access to guideline-based therapy, innovative surgery, and clinical trials. This pilot project is an exploratory multicentre, prospective longitudinal study. It assesses the feasibility, acceptability, implementation and data-quality aspects of the proposed care model and study infrastructure, rather than to determine the effectiveness or causal impact of the interventions. It implements an interdisciplinary, cross-sectoral care model centred on a regional surgical indication tumour board at the National Center for Tumor Diseases (NCT) Dresden. Evidence-based, standardised patient care pathways are developed and piloted across three regional hospitals and two oncology practices. A database using the infrastructure of the NCT Core Unit "Registry Trial Platform", targeted training programmes and "Flying Data Nurses" support coordination, data flow and communication. Patient-reported outcomes complement the clinical data. Routinely collected health insurance data will be used exclusively as external reference data for a descriptive comparison with the MISSION4Sax cohort; no individual-level data linkage will be performed. A mixed-methods process evaluation will be performed alongside the project. The study will assess feasibility in routine care and explore access to specialised care, waiting times, coordination, pathway adherence, and clinical and patient-reported outcomes. Strengthening cancer care infrastructure, interdisciplinary cooperation, and digital systems may support equitable access to high-value care in rural regions. The proposed tumour board, patient pathways, and trained staff may improve care quality and collaboration across sectors. DRKS00036134 (registration date: 30 June 2025).
-
10. Comment on "Privacy-preserving multicenter validation of the RMODscore".
PMID:日期:2026-09-01该文献暂无摘要。